Diabetic endothelial microangiopathy and pulmonary dysfunction

Lanlan Zhang; Faming Jiang; Yingying Xie; Yan Mo; Xin Zhang; Chuntao Liu

doi:10.3389/fendo.2023.1073878

Diabetic endothelial microangiopathy and pulmonary dysfunction

Front Endocrinol (Lausanne). 2023 Mar 21:14:1073878. doi: 10.3389/fendo.2023.1073878. eCollection 2023.

Authors

Lanlan Zhang¹, Faming Jiang¹, Yingying Xie², Yan Mo³, Xin Zhang⁴, Chuntao Liu¹

Affiliations

¹ Department of Respiratory and Critical Care Medicine, Division of Pulmonary Diseases, State Key Laboratory of Biotherapy, West China Hospital of Sichuan University, Chengdu, China.
² Department of Nephrology, Seventh Affiliated Hospital, Sun Yat-sen University, Shenzhen, China.
³ Department of Neurology Medicine, The Aviation Industry Corporation of China (AVIC) 363 Hospital, Chengdu, China.
⁴ Department of Gastroenterology, West China Hospital of Sichuan University, Chengdu, China.

Abstract

Type 2 diabetes mellitus (T2DM) is a widespread metabolic condition with a high global morbidity and mortality rate that affects the whole body. Their primary consequences are mostly caused by the macrovascular and microvascular bed degradation brought on by metabolic, hemodynamic, and inflammatory variables. However, research in recent years has expanded the target organ in T2DM to include the lung. Inflammatory lung diseases also impose a severe financial burden on global healthcare. T2DM has long been recognized as a significant comorbidity that influences the course of various respiratory disorders and their disease progress. The pathogenesis of the glycemic metabolic problem and endothelial microangiopathy of the respiratory disorders have garnered more attention lately, indicating that the two ailments have a shared history. This review aims to outline the connection between T2DM related endothelial cell dysfunction and concomitant respiratory diseases, including Coronavirus disease 2019 (COVID-19), asthma, chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF).

Keywords: COPD; COVID-19; asthma; endothelial cells; type-2 diabetes.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

COVID-19* / complications
Comorbidity
Diabetes Mellitus, Type 2* / complications
Diabetic Angiopathies*
Humans
Idiopathic Pulmonary Fibrosis* / pathology
Lung / pathology
Pulmonary Disease, Chronic Obstructive*
Vascular Diseases*

Grants and funding

Postdoctoral Funding of the Personnel Office-Special Fund for Postdoctoral New Crown Epidemic Prevention and Control (0040204153344), National Science Foundation for Young Scientists of China (81900065), Project supported by the Natural Science Foundation of Sichuan province (2022NSFSC1394), the Youth Innovation Project of Sichuan Medical Association (Q21018), and Chengdu Medical Research Projects (2022516).